US biotech Biogen (Nasdaq: BIIB) raised its annual earnings guidance and reported better-than-expected top and bottom lines for the third quarter of 2024, sending the company’s shares rising 3% in pre-market trading Wednesday.
For the third quarter of 2024, Biogen reported total revenue of $2.47 billion, a slight decrease of 3% compared to the same period in 2023, but a little more than the consensus estimate of $2.43 billion.
Under Generally accepted accounting principal (GAAP) diluted earnings per share (EPS) were $2.66, a substantial improvement from a loss of $0.47 in the third quarter of 2023. Non-GAAP diluted EPS was $4.08, down 6% from $4.36 in the previous year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze